IRB review of psychiatric medication discontinuation and symptom-provoking studies.
Federal regulations governing human subjects research call for additional protections for the "mentally disabled." However, there is currently no consensus definition of mental disability or guidelines for how these research subjects should be protected. This ambiguity complicates the work of institutional review boards (IRBs) charged with the review and approval of protocols involving psychiatric medication discontinuation and symptom provocation. It is particularly important for these studies to be reviewed within the larger context of the research program in which they are conducted. The author proposes a process for IRB review of these studies, which includes the implementation of additional safeguards for subjects determined by the IRB to be vulnerable. Recommendations also are made for training psychiatric clinical investigators in issues related to research bioethics.
Rosenstein
D L
DL
National Institute of Mental Health, Bethesda MD 20892-1277, USA.
D001675:Bioethics; D004334:Drug Administration Schedule; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy*; D011367:Professional Staff Committees; D011570:Psychiatry; D012106:Research / Q000592:standards